In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Valeant Pharmaceuticals International, Inc. VRX, and raised the price target from $183.00 to $223.00.
In the report, Morgan Stanley noted, "We estimate SLXP will be 20% accretive in 2016E, ramping to 37% in 2020E. The significant ramp in long-term accretion is primarily driven by debt paydown and partially by slower projected Salix operating cost expansion under Valeant. We project pro forma EPS to rise as follows: '16E +20% from $12.36 to $14.84, '17E +32% from $14.01 to $18.09, ramping to '20E +37% from $18.89 to $25.89."
Valeant Pharmaceuticals International, Inc. closed on Wednesday at $198.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in